Skip to main
STOK

STOK Stock Forecast & Price Target

STOK Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 13%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Stoke Therapeutics Inc. is positioned favorably in the biotechnology sector, focusing on its proprietary TANGO approach to develop antisense oligonucleotides, particularly zorevunersen, which shows promising results for treating Dravet syndrome. The company's updated revenue projections for zorevunersen suggest enhanced earnings potential, with expectations for a FY28 launch and a target increase to $32, with possibilities for further upside should the FDA expedite the approval process. Furthermore, the strong efficacy data from clinical trials, indicating an approximately 82% seizure reduction and notable cognitive improvements, significantly bolsters confidence in the company’s pipeline and reduces risks associated with the upcoming Phase 3 EMPEROR study.

Bears say

Stoke Therapeutics Inc has experienced a significant 15% pullback in share value, which the analyst considers a misplaced reaction tied to the unrelated FDA filing strategy announcement by QURE. The company is grappling with bleak natural history outcomes for Dravet syndrome, where existing therapies have limited effectiveness, evidenced by declining or plateauing Vineland scores, which may hinder zorevunersen's adoption if it fails to offer substantial long-term benefits. Additionally, there is a substantial risk associated with potential commercial execution failures or the inability to meet market expectations, which could adversely affect the company's stock performance.

STOK has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Stoke Therapeutics Inc (STOK) Forecast

Analysts have given STOK a Strong Buy based on their latest research and market trends.

According to 8 analysts, STOK has a Strong Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Stoke Therapeutics Inc (STOK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.